@article{94d454241e0f4b24a771295288c9d4f8,
title = "Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle",
abstract = "The invasion status of tumour-draining lymph nodes (LNs) is a critical indicator of cancer stage and is important for treatment planning. Clinicians currently use planar scintigraphy and single-photon emission computed tomography (SPECT) with 99m Tc-radiocolloid to guide biopsy and resection of LNs. However, emerging multimodality approaches such as positron emission tomography combined with magnetic resonance imaging (PET/MRI) detect sites of disease with higher sensitivity and accuracy. Here we present a multimodal nanoparticle, 89 Zr-ferumoxytol, for the enhanced detection of LNs with PET/MRI. For genuine translational potential, we leverage a clinical iron oxide formulation, altered with minimal modification for radiolabelling. Axillary drainage in naive mice and from healthy and tumour-bearing prostates was investigated. We demonstrate that 89 Zr-ferumoxytol can be used for high-resolution tomographic studies of lymphatic drainage in preclinical disease models. This nanoparticle platform has significant translational potential to improve preoperative planning for nodal resection and tumour staging.",
author = "Thorek, {Daniel L.J.} and David Ulmert and Diop, {Ndeye Fatou M.} and Lupu, {Mihaela E.} and Doran, {Michael G.} and Ruimin Huang and Abou, {Diane S.} and Larson, {Steven M.} and Jan Grimm",
note = "Funding Information: We thank M. Turkekul, B.J. Beattie and Dr S.-E. Strand for their helpful suggestions. [89Zr]Zr-oxalate was prepared by N. Ramos. D.L.J.T. was supported through the R25T Molecular Imaging Fellowship: Molecular Imaging Training in Oncology (5R25CA096945-07), the 2011 SNM Postdoctoral Molecular Imaging Scholar Award and the Steven Wynn Prostate Cancer Foundation-Young Investigator Award (PCF-YIA). D.U. was supported by the David H. Koch PCF-YIA and M.G.D. by the Geoffrey Beene Cancer Research Center of MSKCC. S.M.L. and H.D.U. were supported by the Center for Targeted Radioimmunotherapy and Diagnosis of the Ludwig Center for Cancer Immunotherapy. J.G. was supported by the Department of Defense Prostate Cancer Research Program of the Congressionally Directed Medical Research Programs under Award No. W81XWH-12-1-0509 (opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the funding agency), the Starr Cancer Consortium (I4-A427), the Louis V. Gerstner Young Investigator Award and the NIH (1R01EB014944-01). The Animal Imaging Core was supported by grants from the NIH: R24 CA83084 and P30 CA08748.",
year = "2014",
month = jan,
day = "20",
doi = "10.1038/ncomms4097",
language = "English (US)",
volume = "5",
journal = "Nature communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
}